Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    David B. Agus, MD

    TitleProfessor of Medicine and Biomedical Engineering
    SchoolKeck School of Medicine of USC
    DepartmentMedicine
    AddressWMB 9033 Wilshire Blvd
    Health Sciences Campus
    Beverly Hills California 90211
    Phone+1 310 272 7640
    Emailagus@usc.edu
    vCardDownload vCard
      Other Positions
      TitleDirector, Lawrence J. Ellison Institute For Transformative Medicine of Usc

      TitleDirector, USC Center For Applied Molecular Medicine


      Collapse Overview 
      Collapse Overview
      Dr. David B. Agus is a professor of medicine and engineering at the University of Southern California Keck School of Medicine and Viterbi School of Engineering and the founding director of USC’s Lawrence J. Ellison Institute for Transformative Medicine.   Dr. Agus leads a multidisciplinary team of researchers dedicated to the development and use of technologies to guide doctors in making health-care decisions tailored to individual needs, and directs a National Cancer Institute Physical Sciences in Oncology Center at USC.  He is a medical oncologist and the co-founder of several personalized medicine companies. Dr. Agus is an international leader in new technologies and approaches for personalized healthcare, serving in leadership roles at the World Economic Forum, among other prestigious organizations. Dr. Agus’ first book called “The End of Illness” was published in 2012 and is a New York Times #1 and international best seller and was the subject of a PBS series, and his most recent books “A Short Guide to a Long Life” and “The Lucky Years: How to Thrive in the Brave New World of Health” are also New York Times and international bestsellers. Dr. Agus graduated cum laude with honors in molecular biology from Princeton University, and received his medical degree from the University of Pennsylvania School of Medicine. He completed his medical internship and residency training at Johns Hopkins Hospital.


      Collapse Biography 
      Collapse Awards and Honors
      American Cancer Society1996  - 2001Physician Research Award
      Sloan-Kettering Institute1996Clinical Scholar Award
      American Cancer Society1994Clinical Oncology Fellowship Award
      HealthNetwork Foundation2008Excellence Award
      Geoffrey Beene Foundation2009Rock Stars of Science™
      Biotech Humanitarian Award2009Selected Judge
      USC Association of Trojan Leagues2013Outstanding Service Award
      American College of Physicians2016Fellow
      Ellis Island Medal of Honor2017Medalist

      Collapse ORNG Applications 
      Collapse Websites
      Collapse Featured Videos
      Collapse In The News
      Collapse Twitter
      Collapse Required Scholarly Project Mentor

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Gross ME, Dorff TB, Quinn DI, Diaz PM, Castellanos OO, Agus D. Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). Clin Genitourin Cancer. 2017 Jul 14. PMID: 28826933.
        View in: PubMed
      2. Kani K, Garri C, Tiemann K, Malihi PD, Punj V, Nguyen AL, Lee J, Hughes LD, Alvarez RM, Wood DM, Joo AY, Katz JE, Agus D, Mallick P. JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines. Mol Cancer Ther. 2017 Aug; 16(8):1645-1657. PMID: 28566434.
        View in: PubMed
      3. Fröbert O, Götberg M, Angerås O, Jonasson L, Erlinge D, Engstrøm T, Persson J, Jensen SE, Omerovic E, James SK, Lagerqvist B, Nilsson J, Kåregren A, Moer R, Yang C, Agus D, Erglis A, Jensen LO, Jakobsen L, Christiansen EH, Pernow J. Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial. Am Heart J. 2017 Jul; 189:94-102. PMID: 28625387.
        View in: PubMed
      4. Agus D, Gaudette É, Goldman DP, Messali A. The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older. PLoS One. 2016; 11(11):e0166103. PMID: 27902693.
        View in: PubMed
      5. Patsch K, Chiu CL, Engeln M, Agus D, Mallick P, Mumenthaler SM, Ruderman D. Single cell dynamic phenotyping. Sci Rep. 2016 Oct 06; 6:34785. PMID: 27708391.
        View in: PubMed
      6. Juarez EF, Lau R, Friedman SH, Ghaffarizadeh A, Jonckheere E, Agus D, Mumenthaler SM, Macklin P. Quantifying differences in cell line population dynamics using CellPD. BMC Syst Biol. 2016 Sep 21; 10(1):92. PMID: 27655224.
        View in: PubMed
      7. Garvey CM, Spiller E, Lindsay D, Chiang CT, Choi NC, Agus D, Mallick P, Foo J, Mumenthaler SM. A high-content image-based method for quantitatively studying context-dependent cell population dynamics. Sci Rep. 2016 Jul 25; 6:29752. PMID: 27452732; PMCID: PMC4958988.
      8. Jones JJ, Wilcox BE, Benz RW, Babbar N, Boragine G, Burrell T, Christie EB, Croner LJ, Cun P, Dillon R, Kairs SN, Kao A, Preston R, Schreckengaust SR, Skor H, Smith WF, You J, Hillis WD, Agus D, Blume JE. A Plasma-Based Protein Marker Panel for Colorectal Cancer Detection Identified by Multiplex Targeted Mass Spectrometry. Clin Colorectal Cancer. 2016 06; 15(2):186-194.e13. PMID: 27237338.
        View in: PubMed
      9. Chiu CL, Patsch K, Cutrale F, Soundararajan A, Agus D, Fraser SE, Ruderman D. Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS). Sci Rep. 2016 Mar 03; 6:22435. PMID: 26936218; PMCID: PMC4776155.
      10. Agus D. THE DOCTOR WILL SEE YOU (AND YOUR DATA) NOW. Fortune. 2016 Jan 01; 173(1):90-3. PMID: 26875351.
        View in: PubMed
      11. Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, Agus D, Pao W, Michor F, Mallick P. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform. 2015; 14(Suppl 4):19-31. PMID: 26244007; PMCID: PMC4504404.
      12. Dzau VJ, Ginsburg GS, Van Nuys K, Agus D, Goldman D. Aligning incentives to fulfil the promise of personalised medicine. Lancet. 2015 May 23; 385(9982):2118-9. PMID: 25957453.
        View in: PubMed
      13. Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol. 2015 Mar 01; 33(7):723-31. PMID: 25624429; PMCID: PMC4879718.
      14. Petrylak DP, Gandhi JG, Clark WR, Heath E, Lin J, Oh WK, Agus D, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. Invest New Drugs. 2015 Apr; 33(2):397-408. PMID: 25556680; PMCID: PMC4390470.
      15. Eisenberg SA, Kurita K, Taylor-Ford M, Agus D, Gross ME, Meyerowitz BE. Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors. Psychooncology. 2015 Feb; 24(2):228-35. PMID: 24891013.
        View in: PubMed
      16. Dreicer R, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, MacVicar GR, Hamid O, Hainsworth J, Gross ME, Shi Y, Webb IJ, Agus D. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014 Mar 01; 20(5):1335-44. PMID: 24418642.
        View in: PubMed
      17. Agus D, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, Damania D, Davies PC, Decuzzi P, Dickinson L, Estevez-Salmeron L, Estrella V, Ferrari M, Fischbach C, Foo J, Fraley SI, Frantz C, Fuhrmann A, Gascard P, Gatenby RA, Geng Y, Gerecht S, Gillies RJ, Godin B, Grady WM, Greenfield A, Hemphill C, Hempstead BL, Hielscher A, Hillis WD, Holland EC, Ibrahim-Hashim A, Jacks T, Johnson RH, Joo A, Katz JE, Kelbauskas L, Kesselman C, King MR, Konstantopoulos K, Kraning-Rush CM, Kuhn P, Kung K, Kwee B, Lakins JN, Lambert G, Liao D, Licht JD, Liphardt JT, Liu L, Lloyd MC, Lyubimova A, Mallick P, Marko J, McCarty OJ, Meldrum DR, Michor F, Mumenthaler SM, Nandakumar V, O'Halloran TV, Oh S, Pasqualini R, Paszek MJ, Philips KG, Poultney CS, Rana K, Reinhart-King CA, Ros R, Semenza GL, Senechal P, Shuler ML, Srinivasan S, Staunton JR, Stypula Y, Subramanian H, Tlsty TD, Tormoen GW, Tseng Y, van Oudenaarden A, Verbridge SS, Wan JC, Weaver VM, Widom J, Will C, Wirtz D, Wojtkowiak J, Wu PH. A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep. 2013; 3:1449. PMID: 23618955; PMCID: PMC3636513.
      18. Gordon MS, Mendelson DS, Gross M, Uttenreuther-Fischer M, Ould-Kaci M, Zhao Y, Stopfer P, Agus D. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013 Apr; 31(2):409-16. PMID: 23242861; PMCID: PMC3589633.
      19. Agus D, Gell-Mann M. Perspective: Meeting of minds. Nature. 2012 Nov 22; 491(7425):S61. PMID: 23320291.
        View in: PubMed
      20. Agus D. Reframe the health debate. Fortune. 2012 Oct 29; 166(7):22. PMID: 23156666.
        View in: PubMed
      21. Chambers MC, Maclean B, Burke R, Amodei D, Ruderman DL, Neumann S, Gatto L, Fischer B, Pratt B, Egertson J, Hoff K, Kessner D, Tasman N, Shulman N, Frewen B, Baker TA, Brusniak MY, Paulse C, Creasy D, Flashner L, Kani K, Moulding C, Seymour SL, Nuwaysir LM, Lefebvre B, Kuhlmann F, Roark J, Rainer P, Detlev S, Hemenway T, Huhmer A, Langridge J, Connolly B, Chadick T, Holly K, Eckels J, Deutsch EW, Moritz RL, Katz JE, Agus D, MacCoss M, Tabb DL, Mallick P. A cross-platform toolkit for mass spectrometry and proteomics. Nat Biotechnol. 2012 Oct; 30(10):918-20. PMID: 23051804; PMCID: PMC3471674.
      22. Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, Agus D, Mallick P, Gross ME. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate. 2013 Feb 15; 73(3):306-15. PMID: 22911164.
        View in: PubMed
      23. Taylor-Ford M, Meyerowitz BE, D'Orazio LM, Christie KM, Gross ME, Agus D. Body image predicts quality of life in men with prostate cancer. Psychooncology. 2013 Apr; 22(4):756-61. PMID: 22422671.
        View in: PubMed
      24. Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross ME, Plevritis SK, McIntosh MW, Jain A, Hanash S, Agus D, Mallick P. Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition. Mol Cancer Ther. 2012 May; 11(5):1071-81. PMID: 22411897; PMCID: PMC3959865.
      25. Mumenthaler SM, Foo J, Leder K, Choi NC, Agus D, Pao W, Mallick P, Michor F. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm. 2011 Dec 05; 8(6):2069-79. PMID: 21995722; PMCID: PMC3230244.
      26. Gross ME, Leichman L, Lowe ES, Swaisland A, Agus D. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemother Pharmacol. 2012 Jan; 69(1):273-80. PMID: 22002543.
        View in: PubMed
      27. Fang Q, Kani K, Faca VM, Zhang W, Zhang Q, Jain A, Hanash S, Agus D, McIntosh MW, Mallick P. Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma. PLoS One. 2011; 6(7):e23090. PMID: 21829587; PMCID: PMC3146523.
      28. Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom-Sternberg S, Beckstrom-Sternberg J, Barrett M, Long J, Chinnaiyan A, Lowey J, Suh E, Pearson JV, Craig DW, Agus D, Pienta KJ, Carpten JD. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 2011 Jan; 21(1):47-55. PMID: 21147910; PMCID: PMC3012925.
      29. Alva A, Slovin S, Daignault S, Carducci M, Dipaola R, Pienta K, Agus D, Cooney K, Chen A, Smith DC, Hussain M. Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs. 2012 Apr; 30(2):749-57. PMID: 21049281; PMCID: PMC3175265.
      30. Mink SR, Hodge A, Agus D, Jain A, Gross ME. Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling. Prostate. 2010 Aug; 70(11):1201-10. PMID: 20564426.
        View in: PubMed
      31. Jiang Y, Palma JF, Agus D, Wang Y, Gross ME. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem. 2010 Sep; 56(9):1492-5. PMID: 20581083.
        View in: PubMed
      32. Mink SR, Vashistha S, Zhang W, Hodge A, Agus D, Jain A. Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs. Mol Cancer Res. 2010 Jun; 8(6):809-20. PMID: 20530582; PMCID: PMC2891820.
      33. Jain A, Penuel E, Mink S, Schmidt J, Hodge A, Favero K, Tindell C, Agus D. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res. 2010 Mar 01; 70(5):1989-99. PMID: 20160029; PMCID: PMC2831105.
      34. Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S, Redkar S, Taverna P, Agus D, Jain A. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther. 2009 Oct; 8(10):2882-93. PMID: 19825806; PMCID: PMC2808126.
      35. Christie KM, Meyerowitz BE, Giedzinska-Simons A, Gross M, Agus D. Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping. Psychooncology. 2009 May; 18(5):508-14. PMID: 18756584.
        View in: PubMed
      36. Bearer EL, Lowengrub JS, Frieboes HB, Chuang YL, Jin F, Wise SM, Ferrari M, Agus D, Cristini V. Multiparameter computational modeling of tumor invasion. Cancer Res. 2009 May 15; 69(10):4493-501. PMID: 19366801; PMCID: PMC2835777.
      37. Luethy R, Kessner DE, Katz JE, Maclean B, Grothe R, Kani K, Faça V, Pitteri S, Hanash S, Agus D, Mallick P. Precursor-ion mass re-estimation improves peptide identification on hybrid instruments. J Proteome Res. 2008 Sep; 7(9):4031-9. PMID: 18707148; PMCID: PMC4673049.
      38. Kessner D, Chambers M, Burke R, Agus D, Mallick P. ProteoWizard: open source software for rapid proteomics tools development. Bioinformatics. 2008 Nov 01; 24(21):2534-6. PMID: 18606607; PMCID: PMC2732273.
      39. Stephan D, Agus D, Nierenberg M, Silver E. Personalized genetics: a responsible approach. Am J Hum Genet. 2008 Jul; 83(1):130; author reply 131. PMID: 18606304; PMCID: PMC2443841.
      40. Pienta KJ, Abate-Shen C, Agus D, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL. The current state of preclinical prostate cancer animal models. Prostate. 2008 May 01; 68(6):629-39. PMID: 18213636; PMCID: PMC3681409.
      41. Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus D. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer. 2007 Jul 27; 7:142. PMID: 17662137; PMCID: PMC1941739.
      42. Gross M, Top I, Laux I, Katz J, Curran J, Tindell C, Agus D. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res. 2007 Apr 01; 13(7):1979-86. PMID: 17404077.
        View in: PubMed
      43. Agus D, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, Kattan MW, Scher HI. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol. 2007 Feb 20; 25(6):675-81. PMID: 17308272.
        View in: PubMed
      44. Dreicer R, Petrylak D, Agus D, Webb I, Roth B. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1208-15. PMID: 17317831.
        View in: PubMed
      45. deVera IE, Katz JE, Agus D. Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery. Clin Adv Hematol Oncol. 2006 Jul; 4(7):541-9. PMID: 17147241.
        View in: PubMed
      46. Shazer RL, Jain A, Galkin AV, Cinman N, Nguyen KN, Natale RB, Gross M, Green L, Bender LI, Holden S, Kaplan L, Agus D. Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU Int. 2006 Apr; 97(4):691-7. PMID: 16536755.
        View in: PubMed
      47. Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S, Miyakawa I, Agus D, Koeffler HP. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer. 2005 Dec 15; 104(12):2701-8. PMID: 16265675.
        View in: PubMed
      48. Katz JE, Mallick P, Agus D. A perspective on protein profiling of blood. BJU Int. 2005 Sep; 96(4):477-82. PMID: 16104895.
        View in: PubMed
      49. Jain A, Tindell CA, Laux I, Hunter JB, Curran J, Galkin A, Afar DE, Aronson N, Shak S, Natale RB, Agus D. Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc Natl Acad Sci U S A. 2005 Aug 16; 102(33):11858-63. PMID: 16087880; PMCID: PMC1187965.
      50. Agus D, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005 Apr 10; 23(11):2534-43. PMID: 15699478.
        View in: PubMed
      51. Jain A, Agus D. PPARgamma signaling: one size fits all? Cell Cycle. 2004 Nov; 3(11):1352-4. PMID: 15467471.
        View in: PubMed
      52. Galkin AV, Mullen L, Fox WD, Brown J, Duncan D, Moreno O, Madison EL, Agus D. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate. 2004 Nov 01; 61(3):228-35. PMID: 15368474.
        View in: PubMed
      53. Hedvat M, Jain A, Carson DA, Leoni LM, Huang G, Holden S, Lu D, Corr M, Fox W, Agus D. Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. Cancer Cell. 2004 Jun; 5(6):565-74. PMID: 15193259.
        View in: PubMed
      54. Shazer RL, Luthringer D, Agus D, Gross ME. Ductal adenocarcinoma of the prostate. Clin Adv Hematol Oncol. 2004 Jun; 2(6):393-5; discussion 396. PMID: 16163211.
        View in: PubMed
      55. Gross ME, Shazer RL, Agus D. Targeting the HER-kinase axis in cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 3):9-20. PMID: 15052539.
        View in: PubMed
      56. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 01; 22(3):537-56. PMID: 14752077.
        View in: PubMed
      57. Gross ME, Jo S, Agus D. Update on HER-kinase-directed therapy in prostate cancer. Clin Adv Hematol Oncol. 2004 Jan; 2(1):53-6, 64. PMID: 16163160.
        View in: PubMed
      58. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus D, Mack DH, Sutherland RL. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003 Jul 15; 63(14):4196-203. PMID: 12874026.
        View in: PubMed
      59. Bonham MJ, Galkin A, Montgomery B, Stahl WL, Agus D, Nelson PS. Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. J Natl Cancer Inst. 2002 Nov 06; 94(21):1641-7. PMID: 12419791.
        View in: PubMed
      60. Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI, Agus D. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res. 2002 Oct; 8(10):3226-31. PMID: 12374693.
        View in: PubMed
      61. Agus D, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002 Aug; 2(2):127-37. PMID: 12204533.
        View in: PubMed
      62. Gery S, Sawyers CL, Agus D, Said JW, Koeffler HP. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene. 2002 Jul 18; 21(31):4739-46. PMID: 12101412.
        View in: PubMed
      63. Roberts WK, Livingston PO, Agus D, Pinilla-Ibarz J, Zelenetz A, Scheinberg DA. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood. 2002 May 15; 99(10):3748-55. PMID: 11986232.
        View in: PubMed
      64. Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus D, Scher HI, Rosen N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res. 2002 May; 8(5):986-93. PMID: 12006510.
        View in: PubMed
      65. Treon SP, Agus D, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC. CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. J Immunother (1991). 2001 May; 24(3):272-279. PMID: 11395644.
        View in: PubMed